A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

The efficacy of azacitidine in patients with anemia and with lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, and the benefit of combining these agents to azacitidine in this setting are not well known. We prospectively compared the outcomes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Haematologica
Hauptverfasser: Thépot, Sylvain, Ben Abdelali, Raouf, Chevret, Sylvie, Renneville, Aline, Beyne-Rauzy, Odile, Prébet, Thomas, Park, Sophie, Stamatoullas, Aspasia, Guerci-Bresler, Agnes, Cheze, Stéphane, Tertian, Gérard, Choufi, Bachra, Legros, Laurence, Bastié, Jean Noel, Delaunay, Jacques, Chaury, Marie Pierre, Sanhes, Laurence, Wattel, Eric, Dreyfus, Francois, Vey, Norbert, Chermat, Fatiha, Preudhomme, Claude, Fenaux, Pierre, Gardin, Claude
Format: Artigo
Sprache:Inglês
Veröffentlicht: Ferrata Storti Foundation 2016
Schlagworte:
Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4967570/
https://ncbi.nlm.nih.gov/pubmed/27229713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.140988
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge